Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 2,101-2,112 of 10,612

Drug study icon

CompletedNCT00500149

Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD

This study is completed in the United States. It is testing time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD.

In United States

ADHDDrugFrom 6 Years to 12 Years

Countries: United States
Sponsor: Shire
Condition: ADHD

Behavioral study icon

CompletedNCT00149812

A Clinic-based Prevention Program for Families of Depressed Mothers

This summary needs review. Please check the official study record and contact the research team for details.

In United States

DepressionBehavioralOver 8 Years

Countries: United States
Sponsor: Johns Hopkins Bloomberg School of Public Health
Condition: Depression

Behavioral study icon

CompletedNCT02697643

A Clinical Decision Support Tool for Electronic Health Records

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionBehavioralOver 18 Years

Countries: United States
Sponsor: Inflexxion, Inc.
Condition: Addiction

Drug study icon

TerminatedNCT05169710

Investigational Drug for depression

This study was terminated in the United States, in Canada, in Bulgaria, .... It is testing investigational Drug for depression.

In United States

Depression, BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, Canada, Bulgaria, ...
Sponsor: Sumitomo Pharma America, Inc.
Condition: Depression, Bipolarity

Drug study icon

CompletedNCT05402111

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05463770

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in people with Schizophrenia

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05542264

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05628103

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05729373

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

This study is completed in the United States, in Bulgaria, in Estonia, .... It focuses on anxiety.

In United States

AnxietyDrugFrom 18 Years to 65 Years

Countries: United States, Bulgaria, Estonia, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Anxiety

Drug study icon

TerminatedNCT04109950

Safety study of investigational Drug in schizophrenia

This study was terminated in the United States, in Bulgaria, in Colombia, .... It is testing investigational Drug for schizophrenia.

In United States

SchizophreniaDrugFrom 13 Years to 65 Years

Countries: United States, Bulgaria, Colombia, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT06316973

Safety study of CS-1103 in Addiction

This study is completed in the United States. It is testing CS-1103 for Addiction.

In United States

AddictionDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Clear Scientific, Inc.
Condition: Addiction

Drug study icon

CompletedNCT04369391

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.